Endodrill vs. Conventional Biopsy. Diagnostics and Genetic Analysis

Sponsor
Region Skane (Other)
Overall Status
Terminated
CT.gov ID
NCT02601079
Collaborator
(none)
7
1
2
33
0.2

Study Details

Study Description

Brief Summary

Endodrill is a new instrument for biopsy sampling in the GI-channel. The purposes of this study are as follows:

  • Compare the Endodrill instrument with conventional biopsy forceps in terms of ability to establish the correct diagnosis based on collected biopsies of tumors in the upper GI tract.

  • Based on the quality of the collected tissue samples we want to evaluate which instrument generates the most useful material for genetic studies of the tumor.

Condition or Disease Intervention/Treatment Phase
  • Device: Endodrill Biopsy
  • Device: Conventional Biopsy forceps
N/A

Detailed Description

Endodrill is a newly constructed biopsy tool for flexible endoscopic use. It uses a drilling motion within a casing to harvest solid biopsies from tissue through the biopsy channel of a conventional flexible endoscope. It was originally designed for sampling of tissue from submucosal lesions. The investigators´ first study of the instrument is now finished. Endodrill is safe to use and generates more submucosal tissue compared to biopsies with a conventional biopsy forceps.

In this study the investigators want to compare the Endodrill instrument´s ability to obtain representative tissue samples from tumors in the distal esophagus and cardia with a conventional biopsy forceps. In addition the investigators want to compare the tissue samples in terms of weight, quality, artefacts and whether either instrument is more suited for collecting tissue for genetic analysis. Such analysis will be conducted with Next-Generation Sequensing (NGS) of the whole exome, Whole Exome Sequensing (WES). In the event of positive results from these analysis the investigators will also conduct RNA-sequencing of the tumor tissue in order to start pre-operative mapping of genetic abnormalities.

20 patients will be enrolled for this study. For each patient the investigators will collect 10 biopsies, 5 biopsies each with conventional biopsy and the Endodrill instrument respectively. The order will be randomized for each patient. For each specific biopsy the investigator will choose a particular site on the suspected tumor tissue without knowing which instrument that will be used for the biopsy. This procedure will be repeated for all 10 biopsies.

Study Design

Study Type:
Interventional
Actual Enrollment :
7 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Endodrill vs. Conventional Biopsy. Diagnostics and Genetic Analysis in Tumors of the Distal Esophagus and Cardia
Actual Study Start Date :
Sep 1, 2016
Actual Primary Completion Date :
May 30, 2019
Actual Study Completion Date :
Jun 1, 2019

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Conventional biopsy

4 out of 8 biopsies taken with a conventional biopsy forceps from the tumor tissue in the distal esophagus and cardia. The biopsies will be taken in random order "blinded" for the person performing the examination. 1 additional biopsy will be taken from the tumor tissue in order to be evaluated for appropriateness of further genetic analysis. Both type of biopsies will be taken from the same patient. In total 10 biopsies per patient.

Device: Conventional Biopsy forceps
Using a conventional biopsy forceps for taking tissue biopsies in the GI tract. The investigators will use conventional biopsy forceps in order to sample high quality biopsies from tumor tissue in the distal esophagus and cardia. The investigators will also investigate to what extent the conventional biopsy forceps can generate biopsies with the correct diagnosis and also evaluate the possibility for genetic studies of the harvested tumor tissue.

Active Comparator: Endodrill biopsy

4 out of 8 biopsies taken with the Endodrill instrument from the tumor tissue in the distal esophagus and cardia. The biopsies will be taken in random order "blinded" for the person performing the examination. 1 additional biopsy will be taken from the tumor tissue in order to be evaluated for appropriateness of further genetic analysis. Both type of biopsies will be taken from the same patient. In total 10 biopsies per patient.

Device: Endodrill Biopsy
Testing a new device for taking tissue biopsies in the GI tract. The investigators will use the Endodrill instrument in order to sample high quality biopsies from tumor tissue in the distal esophagus and cardia. The investigators will also investigate to what extent the Endodrill instrument can generate biopsies with the correct diagnosis and also evaluate the possibility for genetic studies of the harvested tumor tissue.

Outcome Measures

Primary Outcome Measures

  1. Highest proportion (number) of representative biopsies for diagnostic purposes from the tumor tissue. [12 months]

Secondary Outcome Measures

  1. Number of genetic point mutations in tissue harvested from esophageal neoplasms prior to neoadjuvant oncological treatment. [12 months]

  2. Number of fusion genes in tissue harvested from esophageal neoplasms prior to neoadjuvant oncological treatment. [12 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients diagnosed with adenocarcinoma of the distal esophagus/cardia or stomach capable of stating a formal consent to participate in the study.
Exclusion Criteria:
  • Mental illness

  • Extreme co-morbidity (ASA >3)

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Hospital of Lund Lund Skane Sweden 22185

Sponsors and Collaborators

  • Region Skane

Investigators

  • Principal Investigator: Jan Johansson, SrConsultant, Region Skåne

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Martin Jeremiasen, Consultant Surgeon, Region Skane
ClinicalTrials.gov Identifier:
NCT02601079
Other Study ID Numbers:
  • Endodrill I
First Posted:
Nov 10, 2015
Last Update Posted:
Mar 17, 2020
Last Verified:
Mar 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Keywords provided by Martin Jeremiasen, Consultant Surgeon, Region Skane
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 17, 2020